Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Wednesday<br />
March 6 Oral Sessions<br />
Session 49 CROI <strong>2013</strong><br />
C Wednesday, 2:30-4 pm; Hall B2<br />
Poster Abstracts<br />
(see full session listings starting on page 24)<br />
Session 54. ART, Complications, and TB<br />
Session 57. Accessory Proteins/Gag<br />
Session 61. Macrophage HIV Interactions: Cell Biology and Treatment<br />
Session 65. HIV Genotypes and Phenotypes<br />
Session 68. HIV and Monocytes, Macrophages, and Dendritic Cells<br />
Session 72. Microbial Translocation<br />
Session 76. Neutralizing Antibodies and How to Stimulate Them<br />
Session 81. Mechanism of HIV Latency and Reactivation<br />
Session 83. Gene and Adoptive Immunotherapy<br />
Session 91. NeuroAIDS Clinical Studies<br />
Session 92. Neuroimaging Studies<br />
Session 93. Human Genomics<br />
Session 103. Compartment Penetration of ARV<br />
Session 104. ARV Drug Interactions<br />
Session 107. ART: Too Early or Too Late? Or Better Late than Never!<br />
Session 108. ART: Host and Viral Determinants of Outcome<br />
Session 109. ART: Care and Adherence<br />
Session 125. Hepatitis C Virus Epidemiology and Clinical Outcomes<br />
Session 129. HIV-associated Malignancies: Lymphoma<br />
Session 136. Microbial Translocation Measurement and Associations<br />
Session 139. ART Effects: Gene Expression and Cellular Function<br />
Session 140. Frailty: From Mice to Men and Women<br />
Session 142. Renal Disease: Diagnosis, Predictors, and Drugs<br />
Session 145. TB: Incidence, Risk Factors, and Outcomes<br />
Session 146. TB Diagnostics<br />
Session 148. The “ART” of TB Treatment<br />
Session 158. HIV Risk Factors, Prevalence, and Barriers to Care<br />
Session 159. Family Planning: Unintended Pregnancy and Unmet Need<br />
Session 160. HIV in Peri- and Post-menopause<br />
Session 165. Pregnancy Complications among HIV + Women<br />
Session 166. PMTCT: Maternal and Child Health Outcomes<br />
Session 177. HIV and ART-related Complications and Treatment in<br />
Children and Youth<br />
Session 179. Tenofovir in Children<br />
Session 181. Immune Response to Perinatal HIV<br />
Session 182. Response to Pediatric Vaccines in Children and Youth<br />
Session 185. Oral PrEP and ARV Adherence<br />
Session 189. MSM in the Developing World<br />
Session 192. Disease Progression, Morbidity, and Mortality<br />
Session 195. Biological and Behavioral Transmission Risks<br />
Session 196. Reducing Risk<br />
Session 199. Virologic Failure, 2 nd - and 3 rd -line Therapy in RLS<br />
22 � 20th Conference on Retroviruses and Opportunistic Infections<br />
e Wednesday, 4-6 pm; B406<br />
Session 50–Symposium<br />
Progress in Deciphering HIV Protective Immunity,<br />
a symposium in memory of Norman Letvin<br />
Conveners:<br />
Beatrice Hahn, Univ of Pennsylvania,<br />
Philadelphia, US<br />
Gary Nabel, Sanofi, Cambridge, MA, US<br />
158<br />
Viral Escape and Neutralizing Antibody<br />
Evolution in Early HIV-1 Infection<br />
Cynthia Derdeyn<br />
Emory Univ, Atlanta, GA, US<br />
159<br />
The Promise and Challenge of Broad and<br />
Potent Neutralizing Antibody Responses to<br />
HIV-1<br />
Mark Connors<br />
HIV-Specific Immunity Section, NIAID, NIH, Bethesda, MD, US<br />
160<br />
The Role of CD4 T in Developing Durable<br />
Antibody Responses and as HIV Vaccine<br />
Hendrik Streeck<br />
US Military HIV Res Prgm, Walter Reed Army Inst of Res, Henry<br />
M Jackson Fndn, Silver Spring, MD<br />
161<br />
Stringent Control and Eventual Clearance of<br />
Highly Pathogenic SIV by Effector Memory<br />
T Cells<br />
Louis Picker<br />
Vaccine and Gene Therapy Inst, Oregon Natl Primate Res Ctr,<br />
Oregon Hlth and Sci Univ, Beaverton, US<br />
Objectives: This session is directed to clinicians and scientists<br />
interested in basic immunology, the immunology of HIV infection,<br />
or HIV vaccine development. It is assumed that participants will<br />
have some knowledge of basic immunological concepts including<br />
the impact of HIV on the immune system. At the completion of the<br />
session, participants will be knowledgeable about how replicating<br />
vaccine vectors might provide protection against SIV, how different<br />
CD4 T cells populations may be active in fighting HIV infection,<br />
how broadly neutralizing antibodies develop in some HIV + subjects,<br />
and the characteristics and potential uses of newly discovered<br />
broadly neutralizing antibodies.